When can you start PCT after a Cut Stack 150 cycle, given its short esters?

PCT can begin approximately 3–5 days after the last injection of Cut Stack 150. All three esters — Testosterone Propionate, Trenbolone Acetate, and Drostanolone Propionate — carry a 2–3 day half-life, meaning plasma levels fall to sub-suppressive thresholds within a few days. This short window is one of the formulation's practical advantages for users who want to minimise the gap between cycle end and HPTA recovery.

How does PCT start timing after an oral-only cycle differ from an injectable short-ester cycle like Cut Stack 150?

Oral-only PCT timing is governed by hepatic clearance rather than ester hydrolysis — most orals clear within 24–72 hours, so PCT can begin almost immediately after the last dose. Injectable short-ester cycles like Cut Stack 150 add 3–5 days due to ongoing ester hydrolysis in plasma. Long-ester injectable cycles extend that wait to two to four weeks. The mechanism — metabolic clearance versus ester half-life — is the fundamental variable.

Why does the half-life of the last compound injected set the PCT start point?

The androgen receptor remains occupied — and HPG-axis suppression persists — for as long as active compound circulates at suppressive concentrations. The half-life of the longest-acting compound in your last injection determines how long that suppression lasts. With Cut Stack 150, all three compounds share a 2–3 day half-life, so there is no 'slowest ester' delaying the timeline — the PCT window opens uniformly and early.

Why is Cut Stack 150 at 150mg/ml considered suitable for advanced protocols, and how does that concentration affect injection volume?

At 150mg/ml — the lowest concentration in this product group — Cut Stack 150 allows precise, incremental dosing adjustments that higher-concentration blends make harder to calibrate. A 1ml injection delivers exactly 150mg of total active ingredient (50mg each of three compounds), which suits users tracking per-compound exposure carefully. The 10ml vial provides 1,500mg total, enough active ingredient for a structured multi-week cutting cycle.

Is Cut Stack 150 safe for anti-aging or TRT use?

No — Cut Stack 150 is absolutely contraindicated for TRT or anti-aging use. Trenbolone Acetate is approximately five times more androgenic than testosterone and carries progestogenic activity, while Drostanolone Propionate amplifies androgenic load through DHT-class binding. Neither compound is appropriate for hormone replacement objectives. Independent lab testing confirms this product is formulated and released exclusively for advanced cutting protocols. (2) angle_used

Best Value

Hilma Biocare

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Name: Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare
Brand: Hilma Biocare
SKU: INJ-MIX-HIL-150-004
Price: 54.00 EUR
Availability: InStock

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Three short-ester compounds in a single vial eliminate multi-compound injection scheduling complexity.
Drostanolone Propionate's intrinsic aromatase-inhibiting properties reduce exogenous AI dependence during a cut.
2–3 day half-life across all three esters enables one of the earliest PCT initiation windows in the injectable blend category.
1,500mg total active ingredient per 10ml vial delivers full cutting-cycle coverage at a confirmed 150mg/ml concentration.
Independently lab-tested batches with publicly available HPLC and LAL endotoxin certificates per lot number.
150mg/ml concentration allows granular dosing precision — straightforward volume calculations per injection day.
Strict anti-aging/TRT contraindication is documented and communicated, supporting informed protocol planning.

note: Structured for advanced cutting protocols only. Cut Stack 150 is absolutely contraindicated for TRT or anti-aging use. All figures reference the assigned angle context — understanding what this compound is NOT appropriate for.

Phase	dosage	Note
Assessment (Pre-Cycle)	0mg — do not commence	If the objective is TRT or anti-aging hormone maintenance, Cut Stack 150 is contraindicated. Consult an endocrinologist for appropriate testosterone-only protocols.
Advanced Cutting Protocol — Low End	150–300mg total blend / week (1–2ml)	Experienced users only. Inject EOD to maintain stable plasma levels given the 2–3 day half-life of all three esters. HPLC-confirmed concentration at 150mg/ml.
Advanced Cutting Protocol — Moderate	300–450mg total blend / week (2–3ml)	Upper range for structured competitive-preparation cutting phases. Monitor androgenic and progestogenic markers; Trenbolone Acetate's 5× androgenic potency accumulates dose-dependently.
PCT Initiation	Begin ~3–5 days post last injection	Short esters clear rapidly; PCT start is earlier than long-ester injectable cycles and follows a different calculation than oral-only cycles. SERM protocol as per standard suppression management.

Key takeaways

Confirm PCT start 3–5 days after the final short-ester injection.
Distinguish oral-cycle PCT timing from injectable short-ester protocols before planning.
Avoid Cut Stack 150 entirely in any TRT or anti-aging context — absolute contraindication.
Verify batch potency via Hilma Biocare's HPLC lot certificates before use.
Leverage the 150mg/ml concentration for precise per-compound volume control.

Cut Stack 150: A Short-Ester Tri-Compound Defined by What It Is Not

Cut Stack 150 by Hilma Biocare is a 150mg/ml oil-based injectable that delivers Testosterone Propionate 50mg, Trenbolone Acetate 50mg, and Drostanolone Propionate 50mg per millilitre — a clinically-relevant distinction being that this formulation constitutes an advanced cutting stack, not a TRT or anti-aging medication. Testosterone Propionate provides the androgenic base and aromatises at normal testosterone rates; however, the accompanying Trenbolone Acetate carries androgenic potency approximately five times that of testosterone alongside progestogenic activity, while Drostanolone Propionate — a DHT derivative — adds intrinsic aromatase-inhibiting properties and amplifies the overall androgenic load of the blend. Compared to a single-ester TRT protocol built on testosterone enanthate or cypionate, Cut Stack 150 delivers a pharmacological profile that is categorically incompatible with anti-aging or hormone replacement objectives.

Why Cut Stack 150 Is an Absolute Contraindication for TRT Contexts

This blend carries an absolute contraindication for TRT use. Trenbolone Acetate binds the androgen receptor with high affinity and introduces progestogenic HPG-axis suppression distinct from testosterone-only suppression, while Drostanolone Propionate amplifies androgenic exposure through DHT-class receptor binding — neither mechanism belongs in a medically supervised hormone optimisation protocol. The 10ml vial delivers 1,500mg of total active ingredient; that volume and potency exist to serve structured multi-week cutting cycles, not chronic low-dose hormone maintenance. Independent laboratory testing confirms the integrity and stated concentration of every batch, with HPLC-confirmed potency results and LAL endotoxin data available per lot.

PCT Timing: Short Esters, Oral Cycles, and Why the Calculation Differs

All three compounds in Cut Stack 150 share an approximate 2–3 day half-life, which directly governs PCT initiation timing. Post-cycle therapy begins approximately 3–5 days after the final injection — earlier than long-ester injectable protocols, where plasma levels remain suppressive for two to four weeks. Oral-only cycle PCT follows a different logic entirely: because orals clear through hepatic metabolism rather than ester hydrolysis, PCT initiation is driven by compound half-life in hours rather than days. Cut Stack 150's short-ester architecture therefore offers one of the earliest PCT start windows available in the injectable category, a genuine pharmacokinetic advantage for users managing suppression duration.

Analytical Transparency

Hilma Biocare publishes batch-specific certificates covering HPLC concentration verification and LAL endotoxin testing; the lot number on each vial connects directly to its release document, providing a traceable, citation-worthy quality reference for advanced users who cross-reference dosing against confirmed active-ingredient levels.

Usage

Verify the batch lot number on your Hilma Biocare Cut Stack 150 vial against the online certificate database to confirm HPLC-validated potency before any use.
Store the 10ml multi-dose vial at room temperature away from direct light; inspect the oil for particulates or cloudiness before each draw — do not use if either is present.
Calculate your weekly volume based on the confirmed 150mg/ml concentration — 1ml delivers exactly 50mg Testosterone Propionate, 50mg Trenbolone Acetate, and 50mg Drostanolone Propionate; adjust total weekly volume accordingly.
Inject every other day (EOD) to maintain stable blood plasma levels consistent with the 2–3 day half-life shared by all three esters — erratic injection frequency creates unnecessary plasma-level fluctuation.
Monitor for androgenic and progestogenic side effects throughout the cycle; Trenbolone Acetate's approximately fivefold androgenic potency relative to testosterone, confirmed by HPLC-verified compound presence, means androgenic markers should be tracked at minimum bi-weekly.
Plan PCT initiation approximately 3–5 days after the final injection — earlier than long-ester injectable protocols; if you are transitioning from an oral-only cycle to this compound, understand that hepatic-clearance-based PCT timing no longer applies once injectable esters are introduced.

Warnings

contraindications: Cut Stack 150 is absolutely contraindicated for TRT, anti-aging hormone therapy, or any medically supervised hormone replacement protocol. Trenbolone Acetate's progestogenic activity and approximately fivefold androgenic potency versus testosterone, combined with Drostanolone Propionate's DHT-class androgenic amplification, make this blend pharmacologically incompatible with hormone maintenance objectives. Contraindicated in: prostate or breast pathology, cardiovascular disease, hepatic impairment, haematological disorders, pregnancy or lactation.

side_effects: Androgenic: acne, accelerated male-pattern alopecia, virilisation in females. Progestogenic (Trenbolone-derived): potential prolactin elevation, libido suppression. Cardiovascular: haematocrit elevation, lipid profile adverse shift (LDL increase, HDL suppression). Endocrine: significant HPG-axis suppression from both 19-nor and DHT-class components. Night sweats and elevated perspiration are commonly reported with Trenbolone Acetate-containing protocols.

monitoring: Baseline and mid-cycle blood panels: haematocrit, LDL/HDL lipid panel, PSA, liver enzymes (ALT/AST), prolactin, and total/free testosterone. Blood pressure monitoring recommended bi-weekly given Trenbolone's cardiovascular impact profile. HPLC-confirmed concentration means dose-response curves are predictable — deviations in expected markers should prompt immediate reassessment.

pct: Initiate PCT approximately 3–5 days after the final injection of Cut Stack 150, reflecting the 2–3 day half-life of all three propionate and acetate esters. This is materially earlier than long-ester injectable cycles and uses a different timing calculation than oral-only cycle PCT (which follows hepatic clearance rather than ester hydrolysis). A SERM-based PCT protocol is standard; prolactin management should be considered given Trenbolone's 19-nor progestogenic activity.

Frequently asked questions

When can you start PCT after a Cut Stack 150 cycle, given its short esters?: PCT can begin approximately 3–5 days after the last injection of Cut Stack 150. All three esters — Testosterone Propionate, Trenbolone Acetate, and Drostanolone Propionate — carry a 2–3 day half-life, meaning plasma levels fall to sub-suppressive thresholds within a few days. This short window is one of the formulation's practical advantages for users who want to minimise the gap between cycle end and HPTA recovery.
How does PCT start timing after an oral-only cycle differ from an injectable short-ester cycle like Cut Stack 150?: Oral-only PCT timing is governed by hepatic clearance rather than ester hydrolysis — most orals clear within 24–72 hours, so PCT can begin almost immediately after the last dose. Injectable short-ester cycles like Cut Stack 150 add 3–5 days due to ongoing ester hydrolysis in plasma. Long-ester injectable cycles extend that wait to two to four weeks. The mechanism — metabolic clearance versus ester half-life — is the fundamental variable.
Why does the half-life of the last compound injected set the PCT start point?: The androgen receptor remains occupied — and HPG-axis suppression persists — for as long as active compound circulates at suppressive concentrations. The half-life of the longest-acting compound in your last injection determines how long that suppression lasts. With Cut Stack 150, all three compounds share a 2–3 day half-life, so there is no 'slowest ester' delaying the timeline — the PCT window opens uniformly and early.
Why is Cut Stack 150 at 150mg/ml considered suitable for advanced protocols, and how does that concentration affect injection volume?: At 150mg/ml — the lowest concentration in this product group — Cut Stack 150 allows precise, incremental dosing adjustments that higher-concentration blends make harder to calibrate. A 1ml injection delivers exactly 150mg of total active ingredient (50mg each of three compounds), which suits users tracking per-compound exposure carefully. The 10ml vial provides 1,500mg total, enough active ingredient for a structured multi-week cutting cycle.
Is Cut Stack 150 safe for anti-aging or TRT use?: No — Cut Stack 150 is absolutely contraindicated for TRT or anti-aging use. Trenbolone Acetate is approximately five times more androgenic than testosterone and carries progestogenic activity, while Drostanolone Propionate amplifies androgenic load through DHT-class binding. Neither compound is appropriate for hormone replacement objectives. Independent lab testing confirms this product is formulated and released exclusively for advanced cutting protocols. (2) angle_used

Manufacturer

Hilma Biocare's packaging and presentation architecture for Cut Stack 150 reflects a deliberate choice: the 10ml multi-dose vial format is selected over single-use ampoules for this particular formulation because the blend's every-other-day injection frequency — dictated by the 2–3 day half-life of all three propionate and acetate esters — makes repeated access to the same vessel a functional requirement rather than a convenience. The vial's stopper specification, fill volume tolerance, and labelling structure are set at the product level, not shared from a generic multi-compound template; each lot carries its own printed batch number connecting it to a discrete analytical release record that includes HPLC potency data for all three active fractions and LAL endotoxin clearance. This presentation-level specificity is consistent with Hilma Biocare's position that packaging is not cosmetic — it is a pharmacokinetically-informed delivery decision.

Product details

Brand	Hilma Biocare
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Gain Mix, Cut Stack 150, Hilma Biocare Steroid-Mix
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-MIX-HIL-150-004

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Cutting Specialist

Cutaxyl 150 150mg/ml 10ml Vial by Kalpa Pharmaceuticals

Cutaxyl 150 is a GMP-certified tri-ester cutting injectable by Kalpa Pharmaceuticals, combining Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml in a single 10ml multi-dose vial at 150mg/ml total concentration — formulated for compliance-conscious experienced users who demand jurisdiction-verified PCT readiness before the first injection is drawn. All three compounds carry short acetate and propionate ester chains, enabling post-cycle therapy to be scheduled as early as 3–5 days after the final dose, though SERM legal and prescription status varies materially across national regulatory frameworks and must be confirmed in advance. Each production batch exits Kalpa Pharmaceuticals' GMP facility with HPLC-verified active-ingredient concentration, LAL endotoxin clearance, and batch-traceable documentation linked to a specific, dateable manufacturing event.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00